CD49b Targeting Inhibits Tumor Growth and Boosts Anti-tumor Immunity

Pamina Contreras-Kallens, Felipe Gálvez-Jirón, Javiera De Solminihac, Ahmed Elhusseiny, Wilfredo A. González-Arriagada, Francisca Alcayaga-Miranda, Randolph J. Noelle, Karina Pino-Lagos*

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

Resumen

The suppressive function of T-regulatory cells (Tregs) can have a detrimental effect on immune responses against tumor cells. Within the Treg cells subset, a new non-classical population has been reported, which expresses high levels of CD49b molecule and, depending on their activation status, can also express the canonical Tregs transcription factor Foxp3. In this report, we sought to characterize Tregs subsets in a murine melanoma model and disrupt the CD49b/CD29 axis by administering an anti-CD29 antibody in tumor-bearing mice. Our data shows that whereas in the draining lymph nodes, the Tr1 cells subset composes
Idioma originalInglés
Número de artículo928498
Páginas (desde-hasta)928498
PublicaciónFrontiers in Oncology
Volumen12
DOI
EstadoPublicada - 4 jul. 2022

Nota bibliográfica

Copyright © 2022 Contreras-Kallens, Gálvez-Jirón, De Solminihac, Elhusseiny, González-Arriagada, Alcayaga-Miranda, Noelle and Pino-Lagos.

Huella

Profundice en los temas de investigación de 'CD49b Targeting Inhibits Tumor Growth and Boosts Anti-tumor Immunity'. En conjunto forman una huella única.

Citar esto